Yearly Archives: "2015"

EMD Serono announces recipients of the third annual €1 million grant for multiple sclerosis innovation
EMD Serono Announces Recipients of the Third Annual €1 Million Grant for Multiple Sclerosis Innovation Four research grants awarded [...]
Results from ZINBRYTA phase 3 DECIDE study presented at ECTRIMS
Results from ZINBRYTAâ„¢ (Daclizumab High-Yield Process) Phase 3 DECIDE Study Highlighting Efficacy Compared to Interferon Beta-1a [...]
New analysis suggests Aubagio slows brain atrophy in people with Relapsing MS
New Analysis Suggests Aubagio® (teriflunomide) Slows Brain Atrophy in People with Relapsing Multiple Sclerosis Additional MRI data on [...]
Data show effects of TECFIDERA in newly-diagnosed and early disease course multiple sclerosis patients
New Data Show Strong, Sustained Effects of TECFIDERA® (Dimethyl Fumarate) in Newly-Diagnosed and Early Disease Course Multiple Sclerosis [...]
Opexa announces granting of new t-cell patents covering tcelna
THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized [...]
Genzyme introduces “vs.MS”, a global initiative
Genzyme Introduces vs.MS, a Global Initiative Aimed at Uncovering the Often Unspoken Challenges of MS to Drive Better Informed [...]
Genentech’s Ocrelizumab to show efficacy in people with PPMS in large phase III study
Genentech’s Ocrelizumab First Investigational Medicine to Show Efficacy in People with Primary Progressive Multiple Sclerosis in Large [...]
Bayer receives FDA approval for BETACONNECT
Intended for U.S. Media Only Whippany, N.J., September 25, 2015 – Bayer HealthCare announced today that the U.S. Food and Drug [...]
Essential Elements: My Personal Journal
Letter to Patients Understanding MS Managing MS Treatment Options Disease-Modifying Therapies Resources MS Support [...]
Novartis acquires all remaining rights to GSK Ofatumumab to develop treatments for multiple sclerosis
Novartis acquires all remaining rights to GSK’s Ofatumumab to develop treatments for MS and other autoimmune indications Novartis [...]

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us





I have a question about

First

Last




Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM